ANTIVIRAL THERAPY

metrics 2024

Transforming the landscape of antiviral pharmacology.

Introduction

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Metrics 2024

SCIMAGO Journal Rank0.45
Journal Impact Factor1.30
Journal Impact Factor (5 years)1.50
H-Index93
Journal IF Without Self1.30
Eigen Factor0.00
Normal Eigen Factor0.20
Influence0.45
Immediacy Index0.60
Cited Half Life11.10
Citing Half Life6.60
JCI0.22
Total Documents2366
WOS Total Citations1736
SCIMAGO Total Citations22134
SCIMAGO SELF Citations1137
Scopus Journal Rank0.45
Cites / Document (2 Years)1.45
Cites / Document (3 Years)1.47
Cites / Document (4 Years)1.41

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #165/272
Percentile 39.34
Quartile Q3
Infectious Diseases in Medicine
Rank #211/344
Percentile 38.66
Quartile Q3
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #219/313
Percentile 30.03
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 112/132
Percentile 15.50
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 283/354
Percentile 20.20
Quartile Q4
VIROLOGY
Rank 37/41
Percentile 11.00
Quartile Q4

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 116/132
Percentile 12.12
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 309/354
Percentile 12.71
Quartile Q4
VIROLOGY
Rank 39/41
Percentile 4.88
Quartile Q4

Quartile History

Similar Journals

Influenza and Other Respiratory Viruses

Uncovering insights into influenza and beyond.
Publisher: WILEYISSN: 1750-2640Frequency: 6 issues/year

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

INVESTIGATIONAL NEW DRUGS

Pioneering Innovations in Drug Development
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Pioneering insights in pharmacology since 1987.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Journal of Clinical Virology Plus

Shaping the future of virology with cutting-edge findings.
Publisher: ELSEVIERISSN: 2667-0380Frequency: 4 issues/year

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

INTERVIROLOGY

Uncovering breakthroughs in virology and infectious diseases.
Publisher: KARGERISSN: 0300-5526Frequency: 6 issues/year

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

ANTI-CANCER DRUGS

Leading the Charge in Cancer Drug Development
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

Viral Hepatit Dergisi-Viral Hepatitis Journal

Elevating knowledge in viral hepatitis management.
Publisher: GALENOS PUBL HOUSEISSN: 1307-9441Frequency: 3 issues/year

Viral Hepatit Dergisi - Viral Hepatitis Journal, published by GALENOS PUBL HOUSE, is a preeminent journal dedicated to advancing the field of viral hepatitis research. With an ISSN of 1307-9441 and an E-ISSN of 2147-2939, it serves as a vital platform for the dissemination of cutting-edge studies and clinical findings related to the prevention, diagnosis, and treatment of viral hepatitis. The journal aims to foster collaboration among researchers, medical professionals, and students by providing open access to high-quality research articles and reviews. Although specific impact metrics such as H-Index are not detailed, the journal is well-regarded in its field, contributing significantly to the understanding of viral hepatitis and its global implications. Positioned in Istanbul, Turkey, it draws upon a rich academic tradition, ensuring comprehensive coverage of the subject. This journal is indispensable for anyone invested in the fight against viral hepatitis, enriching the scholarly literature while promoting informed practices in healthcare.

Microbiology Spectrum

Exploring the vast landscape of microbial science.
Publisher: AMER SOC MICROBIOLOGYISSN: 2165-0497Frequency: 6 issues/year

Microbiology Spectrum is a prominent peer-reviewed journal published by the American Society for Microbiology, dedicated to advancing the field of microbiology through the dissemination of high-quality research. Since its inception in 2013 and continuing until 2024, the journal has established a strong presence in key domains such as microbiology, immunology, cell biology, and ecology, achieving impressive quartile rankings including Q1 in Infectious Diseases and Q1 in Immunology and Microbiology as of 2023. With an emphasis on open access to its scholarly content, Microbiology Spectrum aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike. The journal's scope encompasses a diverse range of topics pertinent to the field, making it an essential resource for anyone involved in microbiological research and its applications. Researchers looking to publish their findings in a respected journal will find Microbiology Spectrum's robust impact factor and Scopus rankings serve as testament to its significance and influence within the academic community.

AIDS RESEARCH AND HUMAN RETROVIRUSES

Illuminating Pathways in AIDS Research
Publisher: MARY ANN LIEBERT, INCISSN: 0889-2229Frequency: 12 issues/year

AIDS RESEARCH AND HUMAN RETROVIRUSES, published by Mary Ann Liebert, Inc., is a pivotal journal dedicated to advancing the field of HIV research and the broader spectrum of human retroviruses. With an ISSN of 0889-2229 and an E-ISSN of 1931-8405, this journal has been in continuous publication since 1987 and is respected in the academic community for its rigorous peer-reviewed articles. As a Q3 ranked journal in Immunology, Infectious Diseases, and Virology as of 2023, it plays a crucial role in disseminating cutting-edge research, theoretical advancements, and clinical insights that contribute significantly to the understanding and treatment of HIV and related disorders. The journal's objective is to foster collaboration among researchers, healthcare professionals, and educators by providing a platform for the exchange of innovative ideas and findings. Although not an open-access journal, its compelling content ensures that it remains a primary resource for those in the academic and medical communities tackling the challenges posed by retroviral infections. With a commitment to excellence and relevance, AIDS RESEARCH AND HUMAN RETROVIRUSES continues to shape the future of research in this critical area.

Annual Review of Virology

Empowering researchers with in-depth analyses in virology.
Publisher: ANNUAL REVIEWSISSN: 2327-056XFrequency: 1 issue/year

Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.